Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

(2018) Rizwan Romee et al.   BLOOD

Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models

(2018) Bai Liu et al.   CYTOKINE

Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer

(2018) Peter J. Chockley et al.   JOURNAL OF CLINICAL INVESTIGATION

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Expression of checkpoint molecules on myeloid-derived suppressor cells

(2017) Marlene Ballbach et al.   IMMUNOLOGY LETTERS

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade

(2017) Maria Ouzounova et al.   Nature Communications

Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT

(2016) Srinivas Malladi et al.   CELL

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

(2016) Stefani Spranger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells

(2016) A. Spiegel et al.   Cancer Discovery

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells

(2016) Chunwan Lu et al.   OncoImmunology

Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

(2015) Dimitrios Mathios et al.   INTERNATIONAL JOURNAL OF CANCER

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer

(2015) Yi Qing et al.   Drug Design Development and Therapy

Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

(2015) P. R. Rhode et al.   Cancer Immunology Research

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

(2015) Christine Mall et al.   OncoImmunology

Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process

(2014) A. Ardiani et al.   CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

Intravascular staining for discrimination of vascular and tissue leukocytes

(2014) Kristin G Anderson et al.   Nature Protocols

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor  Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

(2013) W. Xu et al.   CANCER RESEARCH

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

(2011) S. Platonova et al.   CANCER RESEARCH

IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

(2011) Kai-ping Han et al.   CYTOKINE

Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer

(2011) Suliman Y. Al Omar et al.   IMMUNOLOGY

Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity

(2009) Zuqiang Liu et al.   JOURNAL OF IMMUNOLOGY

Novel Human Interleukin-15 Agonists

(2009) X. Zhu et al.   JOURNAL OF IMMUNOLOGY